IO Biotech, Inc. (IOBT): Price and Financial Metrics
GET POWR RATINGS... FREE!
IOBT Stock Price Chart Interactive Chart >
IOBT Price/Volume Stats
| Current price | $2.77 | 52-week high | $9.77 |
| Prev. close | $2.55 | 52-week low | $2.15 |
| Day low | $2.50 | Volume | 66,709 |
| Day high | $2.79 | Avg. volume | 132,375 |
| 50-day MA | $2.70 | Dividend yield | N/A |
| 200-day MA | $3.84 | Market Cap | 79.82M |
IO Biotech, Inc. (IOBT) Company Bio
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
Latest IOBT News From Around the Web
Below are the latest news stories about IO BIOTECH INC that investors may wish to consider to help them evaluate IOBT as an investment opportunity.
IO Biotech Announces Appointment of Devin Smith as General CounselMr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel and Chief Compliance Officer. Mr. Smith will oversee all company legal activities and provid |
IO Biotech Provides Business UpdateIndependent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. Encouraging initial data reported from 9 evaluable non-small cell lung cancer patients from the company’s ongoing Phase 2 solid tumor basket trial evaluating IO102-IO103 in combination with pembrolizumab; the comp |
ONCS, BVS and MIMO among mid-day moversGainers: Taboola TBLA +46%.Digital Brands Group (DBGI) +36%.Axsome AXSM +32%.Studio City MSC +27%.Cosmos (COSM) +25%.IO Biotech (IOBT) +22%.The Singing Machine Company (MICS)… |
Analyst Says IO Biotech''s Cancer Treatment Approach ''Differentiated''HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ: IOBT ) with a Buy rating and a price target of $10 . The company''s T-win platform works through a dual mechanism of action that involves the direct killing of immunosuppressive cells and modulation of the tumor microenvironment into a more pro-inflammatory anti-tumor environment. The company''s lead asset, IO102-IO103, is in development for several indications in solid tumors in combination with Merck & Co Inc (NYSE: MRK ) Ketyruda (pembrolizumab), with melanoma being the most advanced indication. The company is now evaluating the IO102-IO103 + pembrolizumab combo in … Full story available on Benzinga.com |
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ: IOBT) with a Buy rating and a price target of $10. The company's T-win platform works through a dual mechanism of action that involves the direct killing of immunosuppressive cells and modulation of the tumor microenvironment into a more pro-inflammatory anti-tumor environment. The company's lead asset, IO102-IO103, is in development for several indications in solid tumors in combination with Merck & Co Inc |
IOBT Price Returns
| 1-mo | 20.43% |
| 3-mo | 13.06% |
| 6-mo | -28.61% |
| 1-year | -67.60% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 20.43% |
| 2022 | -64.06% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...